Acadia Pharmaceuticals vs ANI Pharmaceuticals
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Acadia Pharmaceuticals and ANI Pharmaceuticals side by side, using each oneβs latest annual report. Here is what stands out:
- Acadia Pharmaceuticals is the larger business, with $1.1B of revenue in fiscal 2025 against $883M for ANI Pharmaceuticals.
- ANI Pharmaceuticals grew revenue faster (43.8%, against 11.9%).
- ANI Pharmaceuticals kept more of each dollar of sales as operating profit (12.6% operating margin, against 9.8%).
- ANI Pharmaceuticals turned more of its sales into free cash flow (19.4% FCF margin, against 9.8%).
- Investors pay more for each dollar of ANI Pharmaceuticalsβs earnings: a P/E of 15.7x against 8.8x for Acadia Pharmaceuticals.
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
Acadia Pharmaceuticals
ACAD
3/7
Net marginReturn on equityShare count change
ANI Pharmaceuticals
ANIP
4/7
Revenue growth5-year growthOperating marginFCF margin
Side by side
Best in the row
| Latest fiscal year | ACAD FY25 | ANIP FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $1.6B |
| Revenue | $1.1B | $883M |
| Free cash flow | $105M | $171M |
| Net income | $391M | $78.3M |
| Growth | ||
| Revenue growth | 11.9% | 43.8% |
| 5-year growth | 19.4% | 33.5% |
| Share count change | 2.1% | 9.9% |
| Profitability | ||
| Gross margin | 91.7% | β |
| Operating margin | 9.8% | 12.6% |
| Net margin | 36.5% | 8.9% |
| FCF margin | 9.8% | 19.4% |
| Return on capital | β | 15.9% |
| Return on equity | 39.9% | 16.6% |
| Balance sheet | ||
| Net debt | β | $23.7M |
| Net debt / EBITDA | β | 0.1x |
| Dividends and buybacks | $0.0M | $13.4M |
| Valuation & quality | ||
| P/E | 8.8x | 15.7x |
| Piotroski F-score | β | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.